Ask AI

PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management

Podcast
This activity is available for 0.50 CME/CE credit(s).

Released: October 09, 2026

Expiration: April 08, 2027

See Activity Collection

In this podcast, experts discuss the evolving role of PARP inhibitors in metastatic prostate cancer, with a focus on the biologic rationale for PARP inhibition in tumors with HRR alterations, the importance of germline and somatic genomic testing, and the clinical evidence supporting PARP inhibitor monotherapy and combinations with ARPI. The discussion highlights data from trials including AMPLITUDE and TALAPRO-3, considers how specific HRR alterations may influence treatment selection across metastatic disease settings, and reviews practical strategies for monitoring and managing adverse events such as anemia and nausea. 

PARP Inhibitors in mPC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your podcast.
1.

How many people with prostate cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A patient previously treated for nonmetastatic prostate cancer now develops a supraclavicular lymph node metastasis. His prostate-specific antigen is 0.5 ng/mL. Prior comprehensive germline testing identified no pathogenic variants and somatic testing has not been performed. Archival biopsy tissue from 7 years ago is available. Which testing strategy is most appropriate now?

How confident are you in your answer?
4.

A 72-year-old man with CDK12-mutated metastatic castration-resistant prostate cancer starts talazoparib plus enzalutamide. Over 3 months, his hemoglobin declines from 12.4 to 9.2 g/dL. He reports mild fatigue without bleeding. Iron, vitamin B12, and folate levels are normal, and renal function is unchanged. Based on available evidence and expert recommendation, which action is most appropriate now?

How confident are you in your answer?